Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Medgenics completes its IPO on the NYSE

Executive Summary

Medgenics Inc. (combination therapeutics/devices for sustained treatment of chronic diseases) has netted $10.9mm through its initial public offering on the New York Stock Exchange. After filing in November 2010, the company announced plans two months ago to sell 2.5mm shares for between $4-7 each. It finalized the offering by selling 2.62mm shares (including the overallotment) at $4.54, with five-year warrants to purchase another 2.8mm shares at $6 apiece.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies